Dr. Xavier Escudero and Dr. Jose Luis Levia Pons Discuss: ACC 2023 Wrap-up in Spanish March 6, 2023 Disclosures: TBD
Dr. Ginger Jiang, Dr. Serge Korjian, and Dr. Yazan Daaboul Discuss: ACC 2023 Fellows Wrap-up March 6, 2023 Disclosures: TBD
Dr. Paul Ridker and Dr. C. Michael Gibson Discuss: Residual Inflammatory Risk In Contemporary Statin Treated Patients: A Collaborative Analyses Of 31,197 Participants In The Prominent, Reduce-it, And Strength Trials March 6, 2023 Disclosures: TBD
Katherine Martinez, Dr. Michael Ackerman, Dr. Matthew Martinez and Dr. C. Michael Gibson Discuss: Return-to-play For Elite Level Athletes With Sudden Cardiac Death Predisposing Genetic Heart Diseases March 6, 2023 Disclosures: TBD
Dr. Braden Manns and Dr. Pratik Doshi Discuss: A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases March 6, 2023 Disclosures: TBD
Dr. Ankeet Bhatt and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Virtual Care Team Guided Therapeutic Optimization During Hospitalization in Patients With HFrEF: The IMPLEMENT-HF Study March 6, 2023 Disclosures: TBD
Dr. Barry Borlaug and Dr. C. Michael Gibson Discuss: CAMEO-DAPA Trial: Evaluation of the Mechanism of Benefit For Dapagliflozin in Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial March 6, 2023 Disclosures: TBD
Dr. Rachel Lampert, Dr. Sharlene Day and Dr. C. Michael Gibson Discuss: Vigorous Exercise In Individuals With Hypertrophic Cardiomyopathy (HCM): Primary Results Of The Prospective, Multinational Lifestyle And Exercise In HCM (LIVE-HCM) Study March 6, 2023 Disclosures: TBD
Dr. Myeong-Ki Hong and Dr. C. Michael Gibson Discuss: The LOADSTAR Trial: Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy in Patients With Coronary Artery Disease March 6, 2023 Disclosures: TBD
Dr. Christie Ballantyne and Dr. C. Michael Gibson Discuss: Efficacy And Safety Of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, In The Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial March 6, 2023 Disclosures: TBD
